Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

A team of researchers assessed the immune response after administering a SARS-COV-2 vaccine in immuno-compromised subjects who are potentially at an increased risk to experience severe COVID-19 and inadequate response to SARS-CoV2 vaccination.

17 Jan 2022

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

In a new study, a team of researchers investigated the impact of the fourth dose of a vaccine against COVID-19 in kidney transplant recipients, who had not mounted a humoral immune response to three doses of vaccine.

11 Jan 2022

Booster mRNA vaccination effective in reviving anti-SARS-CoV-2 antibody titers among the elderly

A new study found that a booster dose vaccination against COVID-19 was successful in taking binding. and neutralizing antibodies to levels higher than those observed after the initial double-dose regimen.

7 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Factors associated with SARS-CoV-2 breakthrough infection in fully vaccinated individuals

New study findings showed that the SARS-CoV-2 breakthrough infections are rare and show mild or asymptomatic profiles generally. The breakthrough infection occurs early after vaccination in almost 50% of the cases within 70 to 80 days post full vaccination.

30 Dec 2021

Younger cancer patients at particularly increased risk of mortality from COVID-19

Systematic reviews and meta-analysis were conducted to identify the impact of SARS-CoV-2 in cancer patients based on tumor type, age, and treatment, and any novel risk factors for COVID-19 in cancer patients

21 Dec 2021

A nematode infection can become severe and deadly with the use of corticosteroids

Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.

19 Dec 2021

Scientists develop new immunotherapy for cancer based on transplant rejection mechanism

A team of scientists at the University of Oslo, Oslo University Hospital Radiumhospitalet and Karolinska Institutet, led by Professor Johanna Olweus, has developed a new type of immunotherapy for cancer.

18 Dec 2021

Weak T-cell clonal response to SARS-CoV-2 vaccination in IBD patients deficient in antibody-responders

Researchers investigate the post-vaccination clonal T-cell response and its relationship to antibody responses in IBD patients.

15 Dec 2021

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

Researches have been investigating the possibility of using convalescent plasma to help patients recover from COVID-19.

15 Dec 2021

An assessment of pH-sensitive cationic lipid nanoparticles for drug delivery

A recent review looks at the molecular design of pH-sensitive cationic lipids and their applications for various tissues and cell types.

7 Dec 2021

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

A new study published on the medRxiv* preprint server analyzed the trajectories of anti-SARS-CoV-2 antibodies in patients from the RituxiVac study were compared to healthy volunteers. In addition, they investigated the immunogenicity of a third vaccine dose in previously non-responding patients.

23 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

SARS-CoV-2 reinfection associated with housing instability

Researchers examine the impact of demographic factors and antibody responses following SARS-CoV-2 reinfection.

17 Nov 2021

SARS-CoV-2 protease suppresses host immune response by cleaving NEMO

A recent study conducted by a team of US-based scientists has highlighted a novel function of 3C-like protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The protease has been found to cleave a human immune signaling protein called NF-kB Essential Modulator (NEMO) and disrupt the host immune response.

16 Nov 2021

Immunosuppression News and Research

Further Reading